Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.58 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 7/20 | 0.33 |
| ▸ | TYK2 | P29597 | 7/20 | 0.33 |
| ▸ | JAK1 | P23458 | 6/20 | 0.33 |
| ▸ | JAK3 | P52333 | 6/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875513 | 0.87 | LRRK2 (0.59) | LRRK2PDK2JAK2TYK2JAK1 | |
| SCHEMBL13966403 | 0.84 | LRRK2 (0.66) | LRRK2JAK2TYK2JAK1JAK3 | |
| SCHEMBL875535 | 0.82 | LRRK2 (0.38) | LRRK2PDK2JAK2TYK2JAK1 | |
| SCHEMBL877995 | 0.76 | ACSS2 (0.35) | LRRK2JAK2TYK2JAK1JAK3 | |
| SCHEMBL876616 | 0.73 | LRRK2 (0.60) | LRRK2 | |
| SCHEMBL2630815 | 0.72 | LRRK2 (0.47) | LRRK2 | |
| SCHEMBL883230 | 0.71 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL13966407 | 0.70 | LRRK2 (0.67) | LRRK2PDK2JAK2TYK2JAK1 | |
| SCHEMBL874917 | 0.70 | MAPK1 (0.35) | LRRK2 | |
| SCHEMBL876162 | 0.69 | MAPT (0.36) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| EP-2619201-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | Medical Research Council Technology (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | LRRK2 1512/4885PDK2 68/4885JAK2 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.